Second, immunophenotyping was performed on a relatively small subset of RR-MS patients with the HLA-DRB1*15:01 susceptibility gene who were undergoing natalizumab treatment, raising questions about the generalizability of these findings. This evidence concerns the gene HLA-DRB1 and myeloid sarcoma.